Clinical trials: Prosthetic Joint Infections of Hip
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee
ROADMAP Clinical Trial
Artificial joint infections are treated with different types of antibiotics and surgery. The ROADMAP study aims to find out which treatments currently used work best in regards to surgery, antibiotic choice as well as the time…
- Conditions
- Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Large Joint Prosthetic Joint Infections
- Trial name
- ROADMAP (NCT06771050)
- Testing
- Debridement and Implant Retention (DAIR), Antibiotic Choice, Antibiotic duration Part A - Single stage revision
- Where
- 43 sites in Australia, New Zealand
- Volunteers
- 2,500 people
- Sponsor
- University of Newcastle, Australia
Osteoarthritis, Hip, Total Hip Arthroplasty
Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With OA
Aim: To compare the effect of one single dose versus multiple doses of prophylactic antibiotics administered within 24 hours, on the development of PJI in patients with osteoarthritis undergoing primary THA.
- Conditions
- Osteoarthritis, Hip, Total Hip Arthroplasty, Prosthetic-joint Infection
- Trial name
- ProHipQ-OA (NCT05530551)
- Testing
- Antibiotic dosage practice
- Where
- 36 sites in Denmark
- Volunteers
- 20,000 people
- Sponsor
- Soren Overgaard
Staphylococcus Aureus, Prosthetic Joint Infection
ARTHR-IS (Arthroplasties' Infections Due to Staphylococcus Aureus)
The number of arthroplasties is expected to grow in the next few years. Staphylococcus aureus (SA) is a primary cause of prosthetic joint infection (PJI) with serious consequences.
- Conditions
- Staphylococcus Aureus, Prosthetic Joint Infection, Arthroplasty Complications
- Trial name
- NCT03826108
- Where
- Spain
- Volunteers
- 600 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Prosthetic Joint Infection
Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections
TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making these pathogens substantially more susceptible to established antibiotic treatment regimens.
- Trial name
- NCT04763759
- Testing
- TRL1068, a human monoclonal antibody
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Trellis Bioscience LLC
Prosthesis Related Infections
Biodistribution and Dosimetry Evaluation of [124I]FIAU
This protocol will evaluate the biodistribution and dosimetry of [124I]FIAU in both healthy volunteers and patients with prosthetic joint infections.
- Trial name
- NCT01337466
- Testing
- [124I]FIAU
- Where
- 3 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- BioMed Valley Discoveries, Inc
Prosthetic Joint Infection
Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty
This study will investigate TNP-2092 distribution into joint tissues in participants undergoing a total hip arthroplasty (THA) or a total knee arthroplasty (TKA).
- Trial name
- NCT04294862
- Testing
- TNP-2092
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- TenNor Therapeutics Limited
Prosthetic Joint Infection
Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation
Study Type Prospective, single-arm, open-label, multicenter (3 to 5 sites), interventional trial. Primary Study Objective The objective of the study is to determine the safety profile of local antibiotic irrigation for the…
- Trial name
- NCT03721328
- Testing
- vancomycin hydrochloride and tobramycin sulfate
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Osteal Therapeutics, Inc.
Bone Infection, Osteomyelitis
Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections
Because of its prolonged terminal half-life, dalbavancin is an extremely attractive option in treating Gram-positive infections caused by S. aureus including MRSA, and streptococcal species.
- Conditions
- Bone Infection, Osteomyelitis, Septic Arthritis, Joint Infection
- Trial name
- NCT03426761
- Testing
- Dalbavancin, Vancomycin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Infectious Diseases Physicians, Inc.
Prosthetic Joint Infections of Hip, Bacteriophage Therapy
Bacteriophage Therapy for Staphylococcus Lugdunensis Prosthetic Joint Infection
This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage drug product to treat and prevent the recurrence of a Staphylococcus lugdunensis prosthetic joint infection of the hip.
- Trial name
- NCT07461337
- Testing
- Five phage anti-Staphylococcus aureus bacteriophage cocktail
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Calgary
Hip Prosthesis Infection, Knee Prosthesis Infection
Proof of Concept Study to Assess Safety and Efficacy of Phage Therapy in Hip or Knee Prosthetic Joint Infections Due to Staphylococcus Aureus Treated by DAIR.
Total joint replacements are effective for chronic pain but can lead to Prosthetic Joint Infections (PJI), primarily caused by Staphylococcus aureus and resistant to antibiotics.
- Trial name
- GLORIA (NCT06605651)
- Testing
- Anti-Staphylococcus aureus Bacteriophages (PP1493 and PP1815) intra-articular injection with 0.9% NaCl solution, 0.9% NaCl solution
- Volunteers
- 100 people
- Sponsor
- Phagenix
Prosthesis-related Infections
European Prosthetic Joint Infection Cohort Study- Hip, Knee and Shoulder Prosthetic Joint Infection
The purpose of the study is to compare different approaches for the treatment of prosthetic joint revisions and to optimize the outcomes in patients with prosthetic joint infections (PJI) by improving the treatment concept of PJI.
- Trial name
- EPJIC (NCT02424903)
- Where
- Germany
- Volunteers
- 5,000 people
- Sponsor
- Pro-Implant Foundation
Osteolysis, Arthroplasty Complications
Plasmafit® Revision Structan® Hip Endoprosthesis Cup
The aim of this observational study is to collect clinical and radiological results of the new Plasmafit® Revision Structan® Hip Endoprosthesis Cup in a standard patient population and when used in routine clinical practice.
- Conditions
- Osteolysis, Arthroplasty Complications, Instability of Prosthetic Joint, Degenerative Osteoarthritis
- Trial name
- NCT04255966
- Testing
- Plasmafit® Revision Structan®
- Where
- 4 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Aesculap AG
Fracture of Hip, Total Hip Arthroplasty
Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With a Fracture
Aim: To compare the effect of one single dose versus multiple doses of prophylactic antibiotics administered within 24 hours, on the development of PJI after surgery in patients undergoing primary THA due to an acute fracture or…
- Conditions
- Fracture of Hip, Total Hip Arthroplasty, Prosthetic-joint Infection, Fracture Acetabular
- Trial name
- ProHipQ-F (NCT05530174)
- Testing
- Antibiotic dosage practice
- Where
- 36 sites in Denmark
- Volunteers
- 2,000 people
- Sponsor
- Soren Overgaard
Prosthetic Joint Infection
68Ga-citrate PET/CT for the Diagnosis of Chronic Prosthetic Hip or Knee Infection
Diagnosis of chronic prosthetic joint infection (PJI) can be difficult. 68Ga-citrate Positron Emission Tomography/Computed Tomography (PET/CT) has been recently developed and has many advantages such as high resolution and low…
- Trial name
- Gal-I-TEP (NCT04938193)
- Testing
- 68Ga-citrate PET/CT
- Where
- France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Bordeaux
Staphylococcal Infections
StaphVAX Immunogenicity and Safety in Orthopaedic Joint Surgery
Staphylococcus aureus (S. aureus) is the most common pathogen encountered in infections associated with orthopedic surgery. StaphVAX® is a bivalent S.
- Trial name
- NCT00211965
- Testing
- S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Nabi Biopharmaceuticals
Prosthetic Joint Infections of Hip
Bacteriophage Therapy for Morganella Morganii Prosthetic Joint Infection
This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage drug product to treat and prevent the recurrence of a Morganella morganii prosthetic joint infection of the hip.
- Trial name
- PHAGE-MOM-001 (NCT06814756)
- Testing
- phage therapy
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Calgary
Peri-Prosthetic Joint Infection
IP-coated Revision Hip Implants
The primary aim of the clinical investigation is to demonstrate the efficacy of a silver-based antimicrobial coating on hip implants in the reduction of periprosthetic infections in revision hip arthroplasty due to periprosthetic…
- Trial name
- HIPrevision (NCT06737809)
- Testing
- IP Plasmafit® Revision cup (and stem) system
- Where
- 2 sites in Germany, Poland
- Volunteers
- 268 people
- Sponsor
- Aesculap AG
Prosthetic-joint Infection
A Second Trial of the Abbreviated Protocol Two-Stage Exchange
Apex-2 is a multi-site, parallel group, randomized trial. Patients will be randomly assigned in a 1:1 ratio to the Experimental Arm or the Control Arm.
- Trial name
- Apex-2 (NCT05607030)
- Testing
- VT-X7 Treatment System, Two-stage exchange arthroplasty, SOC Antibiotics
- Where
- 19 sites in United States
- Volunteers
- 76 people
- Sponsor
- Osteal Therapeutics, Inc.
Hip Prosthetic Joint Infection, Knee Prosthetic Joint Infection
Short Interval in Treatment of PJI
Patients with hip, knee and shoulder PJI, will be treated with a two-stage exchange Revision. Patients will be randomized into 2 groups: the experimental Group will get a reimplantation after a short interval (2-3 weeks) while…
- Conditions
- Hip Prosthetic Joint Infection, Knee Prosthetic Joint Infection, Shoulder Prosthetic Joint Infection
- Trial name
- Fast-track (NCT02372435)
- Testing
- Shortening of the interval of two-stage prosthesis exchange
- Volunteers
- 418 people
- Sponsor
- Charite University, Berlin, Germany
Prosthetic Joint Infection
Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)
This is a study designed to evaluate bacteriophage therapy in patients with chronic prosthetic joint infections.
- Trial name
- ACTIVE2 (NCT05269134)
- Testing
- Bacteriophage
- Where
- 10 sites in United States
- Sponsor
- Adaptive Phage Therapeutics, Inc.